| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.59▲ | 4.59▲ | 4.44▲ | 5.01▲ | 4.67▲ |
| MA10 | 4.34▲ | 4.35▲ | 4.24▲ | 4.78▲ | 4.39▲ |
| MA20 | 4.13▲ | 4.16▲ | 4.15▲ | 4.45▲ | 5.08▲ |
| MA50 | N/A | N/A | N/A | 4.19▲ | 6.01▼ |
| MA100 | N/A | N/A | N/A | 5.11▲ | N/A |
| MA200 | N/A | N/A | N/A | 5.84▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | 0.092▲ | N/A |
| RSI | N/A | N/A | N/A | 63.559▲ | N/A |
| STOCH | 89.214▲ | 87.402▲ | 87.402▲ | 78.863 | 61.596 |
| WILL %R | -2.857▲ | -2.857▲ | -2.857▲ | -10.526▲ | -44.674 |
| CCI | 116.092▲ | 116.096▲ | 156.571▲ | 103.646▲ | 68.972 |
|
Monday, November 16, 2020 10:11 PM
Nasdaq: IPHA) (“Innate” or the “Company”) today announced its revenues and cash position for the first nine months of 2020. “In November, we were very pleased that our lead proprietary ...
|
|
Monday, November 16, 2020 10:08 PM
Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines Agency * Monalizumab Phase 3 study initiated, triggering $50 million milestone payment * Cash position of €163.6 ...
|
|
Thursday, November 12, 2020 10:12 PM
Marseille, France, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) ("Innate" or the "Company") today ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 24/11/20 | 5.30 | 5.30 | 5.00 | 5.16 | 13,131 |
| 23/11/20 | 5.05 | 5.08 | 5.02 | 5.02 | 3,700 |
| 20/11/20 | 5.15 | 5.15 | 4.90 | 4.90 | 1,900 |
| 19/11/20 | 5.01 | 5.09 | 4.95 | 4.95 | 2,555 |
| 18/11/20 | 4.93 | 5.284 | 4.93 | 5.02 | 9,200 |
| 17/11/20 | 4.78 | 4.80 | 4.643 | 4.79 | 4,700 |
| 16/11/20 | 4.799 | 4.8004 | 4.46 | 4.59 | 23,643 |
| 13/11/20 | 4.95 | 4.95 | 4.62 | 4.75 | 93,700 |
| 12/11/20 | 4.494 | 4.72 | 4.26 | 4.26 | 26,500 |
| 11/11/20 | 4.34 | 4.71 | 4.10 | 4.385 | 18,000 |
|
|
||||
|
|
||||
|
|